Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Fineline Cube Sep 9, 2026
Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Deals

Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform

Fineline Cube Nov 13, 2025

Complete Genomics, the U.S. subsidiary of MGI Technologies (SHA: 688114), announced today a strategic collaboration...

Company Deals

Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders

Fineline Cube Nov 13, 2025

Degron Therapeutics, a China‑based pioneer in protein‑degradation therapies, today announced the signing of a Letter...

Company Deals

Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research

Fineline Cube Nov 13, 2025

Adicon Holdings Ltd. (HKG: 9860), a leading independent clinic laboratory (ICL) service provider in China,...

Company Deals

AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs

Fineline Cube Nov 13, 2025

AbbVie Inc. (NYSE: ABBV) announced today that it will terminate its long‑standing collaboration agreement with...

Company Deals

ChengDa Biotechnology, IMCAS, and Beijing Key Laboratory for Synthetic Immunology Forge New Frontiers in Vaccine Manufacturing

Fineline Cube Nov 12, 2025

Liaoning ChengDa Biotechnology Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences (IMCAS)...

Company Deals

Sun‑Novo, Byterna, and CAR‑T/CircRNA Collaboration Propel In‑Vivo Gene‑Therapy Frontiers

Fineline Cube Nov 12, 2025

Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. today disclosed a strategic capital injection of RMB 15 million into...

Company Deals

Suzhou Forlong Biotech, Shanghai Henlius, and Engineered Cytokine Immunotherapy Collaboration Announced

Fineline Cube Nov 12, 2025

Suzhou Forlong Biotechnology Co., Ltd. today revealed a strategic partnership with Shanghai Henlius Biotech, Inc....

Company Deals Hospital

GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies

Fineline Cube Nov 12, 2025

GemPharmatech Inc., (SHA: 688046) a global leader in pre‑clinical research solutions and genetically‑engineered mouse models,...

Company Deals

Jinling Pharmaceutical, Nanjing Gulou Hospital, and CD16a Tech‑Transfer Deal Bolsters NK‑Cell Oncology

Fineline Cube Nov 12, 2025

Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing...

Company Deals

Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D

Fineline Cube Nov 12, 2025

Jacobio Pharma Ltd. (HKG: 1167) announced today that its subsidiary Beijing Jacobio Pharmaceuticals Co., Ltd....

Company Deals

Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution

Fineline Cube Nov 12, 2025

Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn. Bhd. (wholly‑owned by Pharmaniaga Berhad) today announced a...

Company Deals

Shandong Buchang’s Luzhou Unit Moves to Secure Exclusive Distribution of Epo‑IgG Fusion in Vietnam

Fineline Cube Nov 12, 2025

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today that its subsidiary Luzhou Buchang will enter...

Others

AnkeBio and PersonGen Ink Capital‑Increase Deal, Secure Exclusive Greater‑China Agency for PA3‑17 CAR‑T Therapy

Fineline Cube Nov 12, 2025

Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today...

Company Drug

Chongqing Precision Biotech Wins NMPA Approval for pCAR‑19B – China’s First Humanised CD19 CAR‑T Therapy for Pediatric B‑ALL

Fineline Cube Nov 12, 2025

Chongqing Precision Biotech Co., Ltd. announced that its pCAR‑19B cell‑based product has received National Medical...

Company Deals Drug

Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)

Fineline Cube Nov 12, 2025

Sino-US biotech Laekna Therapeutics (HKG: 2105) and Qilu Pharmaceutical Co., Ltd. announced today an exclusive...

Company Drug

NMPA Grants Marketing Authorisation to Hefei Amvite’s Memantine Hydrochloride ODT for Alzheimer’s Disease

Fineline Cube Nov 12, 2025

The National Medical Products Administration (NMPA) has approved Memantine Hydrochloride Orally Disintegrating Tablets (ODT) produced...

Company Drug

Shanghai Henlius Biotech Secures UK MHRA Approval for Denosumab Biosimilars BILDYOS & BILPREVDA

Fineline Cube Nov 12, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the United Kingdom’s Medicines and Healthcare Products...

Company

Novo Nordisk Announces Major China Business Restructuring Effective Jan 1 2026

Fineline Cube Nov 12, 2025

Novo Nordisk A/S (NYSE: NVO) released an internal memorandum outlining a sweeping re‑organization of its...

Company Drug

Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) – First PDE‑4 Topical for Atopic Dermatitis in Greater China

Fineline Cube Nov 12, 2025

Huadong Medicine Co., Ltd. (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

Gan & Lee Transfers MedTech Control to Hillhouse Investment, Accelerating Drug Delivery Innovation

Fineline Cube Nov 11, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has transferred its controlling stake...

Posts pagination

1 … 132 133 134 … 718

Recent updates

  • CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops
  • Gilead Opens Foster City Research Center for Oncology and Inflammation
  • Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data
  • China Launches Five-Year Plan to Expand High-Quality Eye Health Services
  • Ascletis Starts US Phase 1 Trial of Oral ASC36 for Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Company Drug

Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data

Policy / Regulatory

China Launches Five-Year Plan to Expand High-Quality Eye Health Services

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.